Physicians' Academy for Cardiovascular Education
How are you managing elevated potassium in your patients with HF and CKD? Ellie Kelepouris and Stephen Greene discuss a multidisciplinary approach.
Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.
Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.
Empagliflozin has been approved by the FDA for the treatment of adults with CKD.
What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.
ESC Congress 2023 The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.
ESC Congress 2023 A prespecified analysis of the ADVOR trial showed that the addition of acetazolamide to loop diuretics increases successful decongestion in patients with acute decompensated HF compared with placebo regardless of baseline renal function.
ESC Congress 2023 A post-hoc analysis of FIDELITY showed that baseline anemia status modifies the effect of finerenone on cardiovascular outcomes, but not renal outcomes, in patients with CKD and T2D.
ESC Congress 2023 What are the main changes in the 2023 update of the 2021 ESC HF guidelines? Theresa McDonagh presents the changes of three updated sections.
ESC Congress 2023 Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.
ESC Congress 2023 Muthiah Vaduganathan shares the results of a pooled analysis of PARAGLIDE-HF and PARAGON-HF that investigated the effects of sacubitril/valsartan on renal outcomes. “Sacubitril/valsartan has meaningful renal protection compared with the angiotensin receptor blocker valsartan”, says Muthiah Vaduganathan.
ESC Congress 2023 A prespecified analysis of the PARAGLIDE-HF and PARAGON-HF trials demonstrated that sacubitril/valsartan compared with valsartan reduces the risk of clinically relevant renal outcomes in patients with HFmrEF/HFpEF.
